vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and NUSCALE POWER Corp (SMR). Click either name above to swap in a different company.

Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $8.2M, roughly 1.6× NUSCALE POWER Corp). On growth, NUSCALE POWER Corp posted the faster year-over-year revenue change (1635.2% vs -57.9%). Over the past eight quarters, NUSCALE POWER Corp's revenue compounded faster (22.4% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

NuScale Power Corporation is a publicly traded American company that designs and markets small modular reactors (SMRs). It is headquartered in Tigard, Oregon. The company's VOYGR power plant, which uses 50 MWe modules and scales to 12 modules, was the first SMR to be certified by the US Nuclear Regulatory Commission (NRC) (2022). The newer 77 MWe module designs, known as the VOYGR-4 and VOYGR-6, were submitted for NRC review on January 1, 2023, and approved May 29, 2025. NuScale is now seekin...

ASRT vs SMR — Head-to-Head

Bigger by revenue
ASRT
ASRT
1.6× larger
ASRT
$13.5M
$8.2M
SMR
Growing faster (revenue YoY)
SMR
SMR
+1693.1% gap
SMR
1635.2%
-57.9%
ASRT
Faster 2-yr revenue CAGR
SMR
SMR
Annualised
SMR
22.4%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q3 FY2025

Metric
ASRT
ASRT
SMR
SMR
Revenue
$13.5M
$8.2M
Net Profit
$-273.3M
Gross Margin
32.9%
Operating Margin
-86.7%
-6532.9%
Net Margin
-3316.2%
Revenue YoY
-57.9%
1635.2%
Net Profit YoY
-1465.5%
EPS (diluted)
$-4.54
$-1.85

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
SMR
SMR
Q4 25
$13.5M
Q3 25
$49.5M
$8.2M
Q2 25
$29.2M
$8.1M
Q1 25
$26.5M
$13.4M
Q4 24
$32.2M
$34.2M
Q3 24
$29.2M
Q2 24
$31.1M
Q1 24
$32.4M
Net Profit
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
$11.4M
$-273.3M
Q2 25
$-16.4M
$-17.6M
Q1 25
$-13.5M
$-14.0M
Q4 24
$-75.0M
Q3 24
$-2.9M
Q2 24
$-3.7M
Q1 24
$-4.5M
Gross Margin
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
32.9%
Q2 25
22.1%
Q1 25
52.4%
Q4 24
91.1%
Q3 24
Q2 24
Q1 24
Operating Margin
ASRT
ASRT
SMR
SMR
Q4 25
-86.7%
Q3 25
23.2%
-6532.9%
Q2 25
-27.5%
-534.9%
Q1 25
-50.0%
-264.1%
Q4 24
-41.9%
-34.6%
Q3 24
-10.4%
Q2 24
-11.6%
Q1 24
-13.4%
Net Margin
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
23.1%
-3316.2%
Q2 25
-56.0%
-219.0%
Q1 25
-51.1%
-104.7%
Q4 24
-219.1%
Q3 24
-10.0%
Q2 24
-11.8%
Q1 24
-13.9%
EPS (diluted)
ASRT
ASRT
SMR
SMR
Q4 25
$-4.54
Q3 25
$0.11
$-1.85
Q2 25
$-0.17
$-0.13
Q1 25
$-0.14
$-0.11
Q4 24
$-3.28
$-0.77
Q3 24
$-0.03
Q2 24
$-0.04
Q1 24
$-0.05

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
SMR
SMR
Cash + ST InvestmentsLiquidity on hand
$63.4M
$691.8M
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$828.7M
Total Assets
$267.0M
$883.1M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
SMR
SMR
Q4 25
$63.4M
Q3 25
$93.4M
$691.8M
Q2 25
$98.2M
$420.7M
Q1 25
$87.3M
$521.4M
Q4 24
$100.1M
$441.6M
Q3 24
$88.6M
Q2 24
$88.4M
Q1 24
$80.7M
Total Debt
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
SMR
SMR
Q4 25
$94.0M
Q3 25
$105.8M
$828.7M
Q2 25
$93.3M
$692.9M
Q1 25
$108.5M
$704.0M
Q4 24
$121.1M
$618.7M
Q3 24
$130.5M
Q2 24
$132.2M
Q1 24
$134.5M
Total Assets
ASRT
ASRT
SMR
SMR
Q4 25
$267.0M
Q3 25
$319.8M
$883.1M
Q2 25
$273.8M
$606.5M
Q1 25
$286.4M
$618.1M
Q4 24
$284.7M
$544.7M
Q3 24
$276.0M
Q2 24
$279.4M
Q1 24
$282.0M
Debt / Equity
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
SMR
SMR
Operating Cash FlowLast quarter
$-30.0M
$-199.8M
Free Cash FlowOCF − Capex
$-199.9M
FCF MarginFCF / Revenue
-2425.1%
Capex IntensityCapex / Revenue
0.9%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
SMR
SMR
Q4 25
$-30.0M
Q3 25
$-4.8M
$-199.8M
Q2 25
$19.1M
$-33.3M
Q1 25
$-12.5M
$-22.8M
Q4 24
$11.5M
$-26.4M
Q3 24
$-35.0K
Q2 24
$7.4M
Q1 24
$7.5M
Free Cash Flow
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
$-199.9M
Q2 25
Q1 25
$-22.9M
Q4 24
$-26.5M
Q3 24
Q2 24
Q1 24
FCF Margin
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
-2425.1%
Q2 25
Q1 25
-170.9%
Q4 24
-77.3%
Q3 24
Q2 24
Q1 24
Capex Intensity
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
0.9%
Q2 25
Q1 25
0.5%
Q4 24
0.1%
Q3 24
0.0%
Q2 24
Q1 24
Cash Conversion
ASRT
ASRT
SMR
SMR
Q4 25
Q3 25
-0.42×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

SMR
SMR

Power Plant And NPM Engineering Design And Licensing Services And Fees$8.0M97%
Other$208.0K3%

Related Comparisons